The company's CendR Platform incorporates novel technologies to enable more effective tumor-targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors and can target immunosuppressive cells within the tumor to enable the patient's immune system and immunotherapies to fight cancer more effectively. Lisata has established partnerships including a global non-exclusive license agreement with Catalent to use certepetide as an SMARTag antibody-drug conjugate payload and a strategic alliance with GATC Health for AI-powered drug discovery.
Cyborg Score Rationale
As of Q3 2025, the company reported $19.0 million in cash and expects available funds to support operations into Q1 2027. While certepetide shows encouraging preclinical and Phase 2 signals with partnership validation, the company faces typical clinical-stage biotech risks with limited runway and dependency on trial outcomes for capital raises.
Top Insights
Lisata was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
Q3 2025 clinical progress included positive preliminary pooled data from ASCEND trial with four complete responses, corroborative data from iLSTA, and encouraging surgical and survival signals from CENDIFOX showing 50% R0 resection, 70% pathologic partial response, and 60% two-year OS in the PDAC subset.
In November 2025, Lisata won Overall BioPharma Solution of the Year at the 2025 BioTech Breakthrough Awards, and Catalent presented data showing certepetide as an ADC payload improved tumor-selective penetration and enhanced ADC efficacy in preclinical models.
As of January 2026, the company's market capitalization was approximately $17 million with about 8.82 million shares outstanding at ~$1.96 per share, with a 52-week range of $1.81 to $4.20.
Named Competitors
Tevoprenem — Oncology therapeutics for solid tumors
ADC Technology Platform — Drug delivery and manufacturing partner (now Lisata's partner)
Oncology Therapeutics — Engineered toxin body therapeutics for solid tumors
Immuno-Oncology Therapies — Checkpoint immunotherapies for solid tumors
Recent Developments
(November 2025) Won BioPharma Solution of the Year award at 2025 BioTech Breakthrough Awards
(October 2025) Announced global non-exclusive license with Catalent to incorporate certepetide into SMARTag antibody-drug conjugate payloads
(November 2025) Reported Q3 2025 results with $19.0 million cash position and funded operations into Q1 2027
Open the full interactive Lisata Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.